Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | ICMT | O60725 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917814 | 0.95 | AR (0.41) | ARMAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL22822157 | 0.95 | AR (0.43) | ARMAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL19917943 | 0.92 | AR (0.37) | ARCYP11B1CYP11B2XDHICMT | |
| SCHEMBL19917917 | 0.92 | AR (0.44) | ARMAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL19903579 | 0.92 | AR (0.36) | ARMAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL19917914 | 0.92 | CYP11B1 (0.37) | ARCYP11B1CYP11B2XDHICMT | |
| SCHEMBL21440728 | 0.90 | AR (0.48) | ARCYP11B1CYP11B2XDHICMT | |
| SCHEMBL22822156 | 0.90 | AR (0.39) | ARXDHICMTSMN1; SMN2RXRA | |
| SCHEMBL19903476 | 0.90 | KIF11 (0.43) | ARCYP11B1CYP11B2PGRRXRA | |
| SCHEMBL19903479 | 0.90 | XDH (0.36) | ARCYP11B1CYP11B2XDHICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10439151-B2 | Organic molecules, especially for use in organic optoelectronic devices | CYNORA GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20180062086-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10439151-B2 | Organic molecules, especially for use in organic optoelectronic devices | OR10J3, ORC3, AOC3 | AR 4190/4885MAOA 455/4885MAOB 393/4885 |
| US-20180062086-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, ORC3, AOC3 | AR 4212/4885MAOA 452/4885MAOB 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.